Center of Medical Biotechnology, Faculty of Biology, University Duisburg-Essen, Universitaetsstrasse, 45141 Essen, Germany.
PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, 34295 Montpellier Cedex 5, France.
Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2113520119. doi: 10.1073/pnas.2113520119. Epub 2022 Mar 29.
SignificanceClassic serine proteases are synthesized as inactive precursors that are proteolytically processed, resulting in irreversible activation. We report an alternative and reversible mechanism of activation that is executed by an inactive protease. This mechanism involves a protein complex between the serine protease HTRA1 and the cysteine protease calpain 2. Surprisingly, activation is restricted as it improves the proteolysis of soluble tau protein but not the dissociation and degradation of its amyloid fibrils, a task that free HTRA1 is efficiently performing. These data exemplify a challenge for protein quality control proteases in the clearing of pathogenic fibrils and suggest a potential for unexpected side effects of chemical modulators targeting PDZ or other domains located at a distance to the active site.
意义经典的丝氨酸蛋白酶以无活性前体的形式合成,然后经过蛋白水解加工,导致不可逆激活。我们报告了一种替代的、可逆的激活机制,该机制由无活性的蛋白酶执行。这种机制涉及丝氨酸蛋白酶 HTRA1 和半胱氨酸蛋白酶钙蛋白酶 2 之间的蛋白质复合物。令人惊讶的是,这种激活是受限的,因为它改善了可溶性 tau 蛋白的蛋白水解,但不能促进其淀粉样纤维的解离和降解,而游离的 HTRA1 可以有效地完成这项任务。这些数据说明了蛋白酶在清除致病纤维方面对蛋白质质量控制的挑战,并暗示了针对 PDZ 或其他位于远离活性位点的结构域的化学调节剂的潜在意外副作用。